Study of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure Without Medications in Newly Diagnosed Glaucoma Patients

What this Trial Is About

Researchers are evaluating the use of Direct Selective Laser Trabeculoplasty (DSLT) to reduce intraocular pressure (IOP) in adults newly diagnosed with primary open-angle glaucoma or similar early-stage glaucomatous conditions, who have not previously received treatment. This study addresses a gap in current research by focusing on treatment-naive patients, aiming to determine if DSLT can provide significant IOP reduction without the need for medications, potentially improving adherence and quality of life. The trial explores whether DSLT can offer a surgical alternative to standard medication-based care for early glaucoma management. Participants will receive the DSLT procedure, which involves applying 120 laser shots at the eye's limbus using a spot size of 400 micrometers and energy between 1.4 to 1.8 millijoules over 2.4 seconds. This procedure is designed to facilitate controlled aqueous outflow to lower IOP. The study measures the percent reduction in IOP from baseline at six months post-procedure to assess effectiveness. During the study, participants will be closely monitored to measure the change in intraocular pressure at six months after treatment. Researchers will evaluate the safety and efficacy of DSLT without the use of postoperative medications. The total involvement includes initial screening, the laser procedure, and follow-up assessments to track IOP changes and any potential side effects over the six-month period.

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients